International Journal of Antimicrobial Agents
Volume 23, Issue 6 , Pages 613-619 , June 2004

In vitro activity of extracts and constituents of Pelagonium against rapidly growing mycobacteria

  • Veronique Seidel

      Affiliations

    • Present address: Department of Pharmaceutical Sciences, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow G4 0NR, Scotland, UK.
    • ,
  • Peter W Taylor

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44-20-7753-5867; fax: +44-20-7753-5867.

Received 24 September 2003 ,Accepted 28 November 2003.

References 

  1. World Health Organisation. The world health report 2001. Geneva: WHO; 2001.
  2. Grange JM, Zumla A. The global emergency of tuberculosis: what is the cause?. J Royal Soc Health. 2002;122:78–81
  3. World Health Organisation. Anti-tuberculosis drug resistance in the world. Report no. 2: prevalence and trends. 2000;WHO/CDS/TB/2000.278.
  4. Pablos-Méndez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull WHO. 2002;80:489–500
  5. O’Brien RJ, Nunn P. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am J Respir Crit Care Med. 2001;162:1055–1058
  6. Cole ST, et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393:537–544
  7. Cole ST. Comparative mycobacterial genomics as a tool for drug target and antigen discovery. Eur Respir J. 2002;36:78s–86s
  8. Newton SM, Lau C, Wright CW. A review of antimycobacterial natural products. Phytother Res. 2000;14:303–322
  9. Cantrell CL, Franzblau SG, Fischer NH. Antimycobacterial plant terpenoids. Planta Med. 2001;67:685–694
  10. Helmstädter A. Umckaloabo—late vindication of a secret remedy. Pharm Historian. 1996;26:2–4
  11. Sechehaye A. The treatment of pulmonary and surgical tuberculosis with Umckaloabo. London: Fraser & Co.; 1930.
  12. Sechehaye A. Umckaloabo and tuberculosis: reports made to the general conference of Romansch-Swiss physicians at the meeting of the Geneva Medical Society. London: Fraser & Co.; 1931.
  13. Sechehaye A. The treatment of tuberculous affections with Umckaloabo. 1st ed. London: Fraser & Co.; 1938.
  14. Bladt S. “Umckaloabo”—Droge der afrikanischen Volksmedizin. Dtsch Apoth Z. 1977;117:1655–1660
  15. van der Walt JJA, Vorster PJ. Pelargoniums of Southern Africa, vol. 3. Kirstenbosch: National Botanic Gardens; 1988.
  16. Watt JM, Breyer-Brandwijk MG. The medicinal and poisonous plants of Southern and Eastern Africa, 2nd ed. London: Livingstone; 1962. p. 454–5.
  17. Heil C, Reitermann U. Atemwegs- und HNO-Infektionen. Therapeutische Erfahrungen mit dem Phytotherapeutikum Umckaloabo®. Therapiewoche Pädiatrie. 1994;7:523–525
  18. Haidvogl M, Schuster MR, Heger M. Akute Bronchitis im Kindesalter—Multizenter-Studie zur Wirksamkeit und Verträglichkeit des Phytotherapeutikums Umckaloabo. Z Phytother. 1996;17:300–313
  19. Kolodziej H, Kayser O. Pelargonium sidoides DC—Neueste Erkenntnisse zum Verständnis des Phytotherapeutikums Umckaloabo. Z Phytother. 1998;19:141–151
  20. Kayser O, Kolodziej H. Highly oxygenated coumarins from Pelargonium sidoides. Phytochemistry. 1995;39:1181–1185
  21. Latté KP, Ferreira D, Venkatraman MS, Kolodziej H. O-galloyl-C-glycosylflavones from Pelargonium reniforme. Phytochemistry. 2002;59:419–424
  22. Bladt S, Wagner H. Cumarindrogen—1. Mitteilung: Quälitatprûfung der Umcka-Droge und ihrer Zubereitungen. Dtsch Apoth Z. 1988;128:292–296
  23. Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med. 1977;63:508–510
  24. Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res. 2001;15:122–126
  25. Koch E, Lanzendorfer-Goossens H, Wohn C. Stimulation of interferon (INF)-β-synthesis and natural killer (NK) cell activity by an aqueous- ethanolic extract from roots of Pelargonium sidoides (Umckaloabo®). N- S- Arch Pharmacol Suppl 1. 2002;365:288
  26. Kolodziej H. Traditionally used Pelargonium species: chemistry and biological activity of umckaloabo extracts and their constituents. Curr Topics Phytochem. 2000;3:77–93
  27. Dunkelblum E, Tan SH, Silk PJ. Double-bond location in monounsaturated fatty acids by dimethyl disulfide derivatisation and mass spectrometry: application to analysis of fatty acids in pheromone glands of four Lepidoptera. J Chem Ecol. 1985;11:265–277
  28. Chung GAC, Aktar Z, Jackson S, Duncan K. High-throughput screen for detecting antimycobacterial agents. Antimicrob Agents Chemother. 1995;39:2235–2238
  29. Gunstone FD, Pollard MR, Scrimgeour CM, Vedanayagam HS. Fatty acids. Part 50. Nuclear magnetic resonance studies of olefinic fatty acids and esters. Chem Phys. Lipids. 1977;18:115–129
  30. Anonymous. Secret remedies: what they cost and what they contain. London: British Medical Association; 1909.
  31. Kolodziej H, Kayser O, Kinderlein AF, et al.  Antileishmanial activity of hydrolysable tannins and their modulatory effects on nitric oxide and tumour necrosis factor-α release in macrophages in vitro. Planta Med. 2001;67:825–832
  32. Kondo E, Kanai K. Further studies on the lethal effect of long-chain fatty acids on mycobacteria. Jpn J Med Sci Biol. 1976;29:25–37
  33. Kondo E, Kanai K. The relationship between the chemical structure of fatty acids and their mycobactericidal activity. Jpn J Med Sci Biol. 1977;30:171–178

PII: S0924-8579(04)00096-2

doi: 10.1016/j.ijantimicag.2003.11.008

International Journal of Antimicrobial Agents
Volume 23, Issue 6 , Pages 613-619 , June 2004

Article Tools

* Image Usage & Resolution